Search Results - "FURUKAWA, MASAYUKI"

Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) by Maruki, Yuta, Morizane, Chigusa, Arai, Yasuhito, Ikeda, Masafumi, Ueno, Makoto, Ioka, Tatsuya, Naganuma, Atsushi, Furukawa, Masayuki, Mizuno, Nobumasa, Uwagawa, Tadashi, Takahara, Naminatsu, Kanai, Masashi, Asagi, Akinori, Shimizu, Satoshi, Miyamoto, Atsushi, Yukisawa, Seigo, Kadokura, Makoto, Kojima, Yasushi, Furuse, Junji, Nakajima, Takako Eguchi, Sudo, Kentaro, Kobayashi, Noritoshi, Hama, Natsuko, Yamanaka, Takeharu, Shibata, Tatsuhiro, Okusaka, Takuji

“…Background Fibroblast growth factor receptor 2 ( FGFR2 ) rearrangement is expected to be a novel therapeutic target in advanced/recurrent biliary tract cancer…”
Get full text

In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan by Fujiki, Hiroyuki, Matsunaga, Masayuki, Furukawa, Masayuki, Yamashita, Tatsuya, Nakamura, Shigeki, Miyazaki, Toshiki, Mizuguchi, Hiroshi, Menjo, Yasuhiro, Matsuda, Takakuni, Yamada, Yoshihisa

“…Tolvaptan is an orally active vasopressin V2 receptor antagonist and used for the treatment of volume overload in some disease as an aquaretic. Tolvaptan…”
Get full text

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial by Kudo, Masatoshi, Okusaka, Takuji, Motomura, Kenta, Ohno, Izumi, Morimoto, Manabu, Seo, Satoru, Wada, Yoshiyuki, Sato, Shinpei, Yamashita, Tatsuya, Furukawa, Masayuki, Aramaki, Takeshi, Nadano, Seijin, Ohkawa, Kazuyoshi, Fujii, Hirofumi, Kudo, Toshihiro, Furuse, Junji, Takai, Hiroki, Homma, Gosuke, Yoshikawa, Reigetsu, Zhu, Andrew X.

“…Background The global, randomized, phase 3 REACH-2 study (ClinicalTrials.gov identifier: NCT02435433) found significantly longer overall survival (OS) for…”
Get full text

Multicenter Study of Congenital Middle Ear Anomalies. Report on 246 Ears by Ito, Tsukasa, Furukawa, Takatoshi, Ohshima, Shinsuke, Takahashi, Kuniyuki, Takata, Yusuke, Furukawa, Masayuki, Hiraumi, Harukazu, Yamauchi, Daisuke, Yuasa, Yu, Goto, Shinichi, Sasaki, Akira, Koizumi, Koh, Otsuki, Koshi, Imaizumi, Mitsuyoshi

“…Objectives/Hypothesis Congenital middle ear anomalies represent a relatively rare condition. This study aimed to describe the characteristics and the surgical…”
Get full text

Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS‐PC Study by Yamaue, Hiroki, Tsunoda, Takuya, Tani, Masaji, Miyazawa, Motoki, Yamao, Kenji, Mizuno, Nobumasa, Okusaka, Takuji, Ueno, Hideki, Boku, Narikazu, Fukutomi, Akira, Ishii, Hiroshi, Ohkawa, Shinichi, Furukawa, Masayuki, Maguchi, Hiroyuki, Ikeda, Masafumi, Togashi, Yosuke, Nishio, Kazuto, Ohashi, Yasuo

“…Gemcitabine is a key drug for the treatment of pancreatic cancer; however, with its limitation in clinical benefits, the development of another potent…”
Get full text

Association Between Earwax-Determinant Genotypes and Acquired Middle Ear Cholesteatoma in a Japanese Population by Hara, Satoshi, Kusunoki, Takeshi, Nakagawa, Hiroshi, Toyoda, Yu, Nojiri, Shuko, Kamiya, Kazusaku, Furukawa, Masayuki, Takata, Yusuke, Okada, Hiroko, Anzai, Takashi, Matsumoto, Fumihiko, Ikeda, Katsuhisa

“…Objective A single-nucleotide polymorphism 538G>A in the human ABCC11 gene is a determinant of the earwax morphotype. ABCC11 538GG and GA correspond to wet…”
Get full text

Protocol of a randomized phase II/III study of gemcitabine plus nab-paclitaxel combination therapy versus modified FOLFIRINOX versus S-IROX for metastatic or recurrent pancreatic cancer: JCOG1611 (GENERATE) by Mizusawa, Junki, Ohba, Akihiro, Ozaka, Masato, Katayama, Hiroshi, Okusaka, Takuji, Kobayashi, Satoshi, Ikeda, Masafumi, Terashima, Takeshi, Sasahira, Naoki, Okano, Naohiro, Miki, Ikuya, Kaneko, Takashi, Mizuno, Nobumasa, Todaka, Akiko, Furukawa, Masayuki, Kajiura, Shinya, Kataoka, Tomoko, Fukuda, Haruhiko, Furuse, Junji, Ueno, Makoto

“…Gemcitabine plus nab-paclitaxel and combination chemotherapy with fluorouracil, leucovorin, irinotecan and oxaliplatin are a standard treatment for metastatic…”
Get full text

Enantioselective analysis of tolvaptan in rat and dog sera by high-performance liquid chromatography and application to pharmacokinetic study by Furukawa, Masayuki, Yamasaki, Yuko, Hirao, Yukihiro, Umehara, Ken

“…•HPLC method was validated for the determination of tolvaptan enantiomers in rat and dog sera.•Transformation of S-form to R-form of tolvaptan was occurred in…”
Get full text

Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study by Azemoto, Nobuaki, Ueno, Makoto, Yanagimoto, Hiroaki, Mizuno, Nobumasa, Kawamoto, Yasuyuki, Maruki, Yuta, Watanabe, Kazuo, Suzuki, Rei, Kaneko, Junichi, Hisada, Yuya, Sato, Hiroki, Kobayashi, Satoshi, Miyata, Hideki, Furukawa, Masayuki, Mizukami, Takuro, Miwa, Haruo, Ohno, Yoshinori, Tsuji, Kunihiro, Tsujimoto, Akiko, Nagano, Hiroaki, Okuyama, Hiroyuki, Asagi, Akinori, Okano, Naohiro, Ishii, Hiroshi, Morizane, Chigusa, Ikeda, Masafumi, Furuse, Junji

“…Abstract Background Endoscopic duodenal stent placement is an alternative technique to gastrojejunostomy for gastric outlet obstruction due to pancreatic…”
Get full text

nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients by Ueno, Makoto, Nakamori, Shoji, Sugimori, Kazuya, Kanai, Masashi, Ikeda, Masafumi, Ozaka, Masato, Furukawa, Masayuki, Okusaka, Takuji, Kawabe, Ken, Furuse, Junji, Komatsu, Yoshito, Ishii, Hiroshi, Sato, Atsushi, Shimizu, Satoshi, Chugh, Priti, Tang, Rui, Ioka, Tatsuya

“…Background In the NAPOLI‐1 phase 3 trial, liposomal irinotecan (nal‐IRI) +5‐fluorouracil/leucovorin (5‐FU/LV) significantly increased mPFS versus 5‐FU/LV (3.1…”
Get full text

The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 by Yamada, Ikuhiro, Morizane, Chigusa, Okusaka, Takuji, Mizusawa, Junki, Kataoka, Tomoko, Ueno, Makoto, Ikeda, Masafumi, Okano, Naohiro, Todaka, Akiko, Shimizu, Satoshi, Mizuno, Nobumasa, Sekimoto, Mitsugu, Tobimatsu, Kazutoshi, Yamaguchi, Hironori, Nishina, Tomohiro, Shirakawa, Hirofumi, Kojima, Yasushi, Oono, Takamasa, Kawamoto, Yasuyuki, Furukawa, Masayuki, Iwai, Tomohisa, Sudo, Kentaro, Okamura, Keiya, Yamashita, Tatsuya, Kato, Naoya, Shioji, Kazuhiko, Shimizu, Kyouko, Nakagohri, Toshio, Kamata, Ken, Ishii, Hiroshi, Furuse, Junji

“…In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good…”
Get full text

FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies by Fujiwara, Yutaka, Kuboki, Yasutoshi, Furukawa, Masayuki, Mizuno, Nobumasa, Hara, Hiroki, Ioka, Tatsuya, Ueno, Makoto, Takahashi, Yasuo, Takahashi, Shunji, Takeuchi, Shinji, Lihou, Christine, Ji, Tao, Tian, Chenwei, Shimizu, Toshio

“…Background FIGHT‐102 was a phase 1, dose‐escalation, dose‐expansion study of pemigatinib in Japanese patients with advanced solid tumors. Here, we report…”
Get full text

Eotaxin-1, -2, and -3 immunoreactivity and protein concentration in the nasal polyps of eosinophilic chronic rhinosinusitis patients by Yao, Toru, Kojima, Yuko, Koyanagi, Akemi, Yokoi, Hidenori, Saito, Tatsuya, Kawano, Kenji, Furukawa, Masayuki, Kusunoki, Takeshi, Ikeda, Katsuhisa

“…Objectives/Hypothesis: Eosinophilic chronic rhinosinusitis (CRS) is characterized by the accumulation of numerous eosinophils in the sinus mucosa and nasal…”
Get full text

Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 by Ueno, Makoto, Morizane, Chigusa, Okusaka, Takuji, Mizusawa, Junki, Kataoka, Tomoko, Ikeda, Masafumi, Ozaka, Masato, Okano, Naohiro, Sugimori, Kazuya, Todaka, Akiko, Shimizu, Satoshi, Mizuno, Nobumasa, Yamamoto, Tomohisa, Sano, Keiji, Tobimatsu, Kazutoshi, Katanuma, Akio, Miyamoto, Atsushi, Yamaguchi, Hironori, Nishina, Tomohiro, Shirakawa, Hirofumi, Kojima, Yasushi, Oono, Takamasa, Kawamoto, Yasuyuki, Furukawa, Masayuki, Iwai, Tomohisa, Sudo, Kentaro, Miyakawa, Hiroyuki, Yamashita, Tatsuya, Yasuda, Ichirou, Takahashi, Hidenori, Kato, Naoya, Shioji, Kazuhiko, Shimizu, Kyoko, Nakagohri, Toshio, Kamata, Ken, Ishii, Hiroshi, Furuse, Junji

“…JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior…”
Get full text

Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) by Maruki, Yuta, Morizane, Chigusa, Arai, Yasuhito, Ikeda, Masafumi, Ueno, Makoto, Ioka, Tatsuya, Naganuma, Atsushi, Furukawa, Masayuki, Mizuno, Nobumasa, Uwagawa, Tadashi, Takahara, Naminatsu, Kanai, Masashi, Asagi, Akinori, Shimizu, Satoshi, Miyamoto, Atsushi, Yukisawa, Seigo, Kadokura, Makoto, Kojima, Yasushi, Furuse, Junji, Nakajima, Takako Eguchi, Sudo, Kentaro, Kobayashi, Noritoshi, Hama, Natsuko, Yamanaka, Takeharu, Shibata, Tatsuhiro, Okusaka, Takuji

“…The original article has been corrected…”
Get full text

A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy by Katsuda, Masahiro, Miyazawa, Motoki, Ojima, Toshiyasu, Katanuma, Akio, Hakamada, Kenichi, Sudo, Kentaro, Asahara, Shingo, Endo, Itaru, Ueno, Makoto, Hara, Kazuo, Yamada, Suguru, Fujii, Tsutomu, Satoi, Sohei, Ioka, Tatsuya, Ohira, Masaichi, Akahori, Takahiro, Kitano, Masayuki, Nagano, Hiroaki, Furukawa, Masayuki, Adachi, Tomohiko, Yamaue, Hiroki

“…Pancreatic cancer is a refractory malignancy, and the development of a new effective treatment strategy is needed. We generated a dendritic cell vaccine by…”
Get full text

A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy by Ueno, Makoto, Morizane, Chigusa, Furukawa, Masayuki, Sakai, Daisuke, Komatsu, Yoshito, Nakai, Yousuke, Tsuda, Masahiro, Ozaka, Masato, Mizuno, Nobumasa, Muto, Manabu, Fukutomi, Akira, Ikeda, Masafumi, Tsuji, Akihito, Katanuma, Akio, Moriwaki, Toshikazu, Kajiwara, Takeshi, Ishii, Hiroshi, Negoro, Yuji, Shimizu, Satoshi, Nemoto, Noriko, Kobayashi, Shingo, Makino, Keigo, Furuse, Junji

“…Purpose Effective second‐line chemotherapy options are limited in treating advanced biliary tract cancers (BTCs). Resminostat is an oral histone deacetylase…”
Get full text

Nonclinical Pharmacokinetics of a New Nonpeptide V2 Receptor Antagonist, Tolvaptan by Furukawa, Masayuki, Umehara, Ken, Kashiyama, Eiji

“…Purpose To evaluate the pharmacokinetic profile of tolvaptan. Method The nonclinical pharmacokinetic profile of [ 14 C]tolvaptan was evaluated in an…”
Get full text

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects by Shoaf, Susan E., Ohzone, Yoshihiro, Ninomiya, Shin-ichi, Furukawa, Masayuki, Bricmont, Patricia, Kashiyama, Eiji, Mallikaarjun, Suresh

“…Interactions between tolvaptan and digoxin were determined in an open‐label, sequential study where 14 healthy subjects received tolvaptan 60 mg once daily…”
Get full text

Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma by Sugimoto, Rie, Inada, Hiroki, Tanaka, Yuki, Senju, Takeshi, Aratake, Yoshifusa, Nakanishi, Akira, Miki, Masami, Lee, Lingaku, Hisano, Terumasa, Matsumoto, Yoshihiro, Mano, Yohei, Iguchi, Tomohiro, Sugimachi, Keishi, Okumura, Yukihiko, Taguchi, Kenichi, Furukawa, Masayuki

“…Use of lenvatinib, which has a high response rate in advanced hepatocellular carcinoma, sometimes results in tumor shrinkage and resectability of previously…”
Get full text